New drug AGX101 targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This study tests a new drug called AGX101 in people with advanced solid tumors that have not responded to standard treatments. The drug is given through a vein and aims to shrink or control tumors. The main goals are to find the safest dose and understand side effects. About 80 p…
Phase: PHASE1 • Sponsor: Angiex, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC